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Efﬁcacy of zonisamide—our experience
Commentary on Yamauchi
Gregoy K. Bergey*
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
Dr. Bergey
Dr. Yamauchi has pointed out that those patients re-
ceiving polytherapy did not do as well as those re-
ceiving zonisamide monotherapy. He backed up his
observations with blood levels of zonisamide for all
the groups. I believe that his observations suggest
that the zonisamide dose should be higher, unless
the side effects become limiting.
Dr. Yamauchi
As this was a retrospective study, detailed analyses
were not carried out on each patient. For those
patients who did not develop side effects, the zon-
isamide dose should have been increased. There
were some patients whose dose was increased,
but not sufﬁciently. In hindsight, we could have
increased the dose even more.
Dr. Bergey
Patients with Lennox-Gastaut syndrome have sev-
eral different seizure types. Howwere the different
types evaluated?
Dr. Yamauchi
We did not go into that much detail in classifying the
improvement rate according to seizure type within
a syndrome.
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Audience member
We are all intrigued with your experience in treat-
ing patients with idiopathic spike-and-wave dis-
ease. We have found valproate to be useful in some
cases, but it has some unacceptable side effects.
Do any of your patients who have failed therapy
with valproate respond to zonisamide?
Dr. Yamauchi
In our experience zonisamide is not often effective
for atypical absence seizures.
Audience member
Have you had good results with zonisamide com-
pared to valproate in patients with tonic-clonic
seizures and spike-and-wave disease?
Dr. Yamauchi
It is difﬁcult to answer that question, because gen-
erally if the patient responds to the ﬁrst drug we
will not try to switch them to another. We have yet
to carry out a comparison trial.
In my experience, until a drug has been used for
more than 10 years it is regarded as a new drug, and
it generally is not the ﬁrst choice for monotherapy.
Now zonisamide has been used in Japan for more
than 10 years and we are beginning to act as if it is
no longer new.
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